Navigation Links
Techne Announces Resignation Of Chief Financial Officer Gregory Melsen
Date:1/2/2014

MINNEAPOLIS, Jan. 2, 2014 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) today announced that Gregory J. Melsen will resign from his position as Chief Financial Officer, effective February 3, 2014, to pursue other opportunities.  Mr. Melsen has served as Techne's Chief Financial Officer since 2004.

Techne has begun the process of identifying a successor to Mr. Melsen and expects to announce the appointment of such successor in the coming months.

"I would like to thank Greg for his immense contributions to Techne during the past nine years," stated Charles Kummeth, President and Chief Executive Officer of Techne.  "Greg was instrumental in the recent leadership transition, and the experienced financial team that Greg has put in place will ensure that the current transition is seamless.  On behalf of Techne, I wish Greg all the best for the future."

Mr. Melsen said, "Being Chief Financial Officer of Techne has been a great professional experience, and I look forward to watching the Company continue to execute the strategies that have recently been put into place."

About Techne Corporation

Techne Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through the Company's two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens, Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits.  Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products.  Bionostics is a leading supplier of control solutions used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation. Tocris is a leading supplier of chemical reagents for non-clinical life science research.

Forward-Looking Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "intend" or similar words.  The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the integration of new leadership, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.


'/>"/>
SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
2. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
3. Techne Corporation Releases Unaudited Second Quarter And Six Month Fiscal Year 2013 Results
4. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
5. Techne Corporation Releases Unaudited First Quarter Fiscal Year 2014 Results
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/26/2016)... New York , May 26, 2016 ... Market Research "Medical Waste Management Market - U.S. Industry Analysis, ... medical waste management market in the U.S. was valued at ... at a CAGR of 3.4% from 2015 to 2023 to ... provides exhaustive analysis of current and emerging needle free drug ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... , ... Two director-level employees of Horizon Blue Cross Blue Shield of New ... honorees. The award recognizes businesswomen who excel in their fields and who have ... MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, ...
(Date:5/27/2016)... ... , ... With over 60 percent of acute stroke survivors being left unable ... aid in the rehabilitation process has steadily increased. Ekso Bionics had been working to ... to stroke. , Ekso Bionics has now received clearance from the U.S. Food and ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... Mediaplanet to help educate the many who are unaware of the plight of ... aphasia will run within the “Stroke Awareness” campaign. , The link between stroke ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
Breaking Medicine News(10 mins):